Physician profile
Brett Bird
NPI 1780453191
$1,371.99
in general payments reported to CMS, 2019-2025
20 companies · $916 in 2025
The $916 reported for 2025 was more than what 83% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $456 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $294.10 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $242.41 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.00 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Lilly USA, LLC | $83.84 | 2024-2025 | Mounjaro |
| Dexcom, INC. | $78.98 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $77.62 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.36 | 2025 | |
| Merck Sharp & Dohme LLC | $52.11 | 2024-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Mylan Specialty L.P. | $41.06 | 2024 | Yupelri |
| Astellas Pharma US INC | $33.05 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $32.32 | 2025 | Breztri |
| Vertex Pharmaceuticals Incorporated | $32.30 | 2025 | |
| Amgen INC. | $30.77 | 2024 | Repatha, Otezla |
| Corcept Therapeutics | $29.09 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $26.39 | 2025 | Trelegy Ellipta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $23.34 | 2025 | Vyjuvek |
| Abbvie INC. | $16.99 | 2025 | |
| Fidia Pharma USA INC. | $16.92 | 2025 | Hymovis, Triluron |
| Boston Scientific Corporation | $16.01 | 2024 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $15.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.